Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 11

Current treatment options for acanthosis nigricans

Authors Patel NU, Roach C, Alinia H, Huang WW, Feldman SR

Received 7 November 2017

Accepted for publication 5 April 2018

Published 7 August 2018 Volume 2018:11 Pages 407—413

DOI https://doi.org/10.2147/CCID.S137527

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Nupur U Patel,1 Catherine Roach,1 Hossein Alinia,1 William W Huang,1 Steven R Feldman1–3

1Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, 2Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, 3Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Abstract: Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. While the goal of therapy is to treat the primary cause, cosmetic resolution of AN lesions can be important for patients and their quality of life. Treatment options for AN have not been extensively studied; however, smaller powered clinical trials and case reports exist in the literature. Our review aims to explore and evaluate the current treatment options that exist for AN.

Keywords: acanthosis nigricans, diabetes, obesity, hyperinsulinemia, dermatologic condition, dermatology, malignant acanthosis, pseudoacanthosis, metformin, isotretinoin, tretinoin, topical therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]